Dr.Reddys Lab (BSE: 500124) is a Hyderabad, Telangana-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹1,02,010 Cr, it ranks #100 by market cap among the 6,189 Indian listed companies on FinBizNet, and #5 of 86 in Medicinal Chemicals and Botanical Products. At ₹1,224.50 (as of 26 Oct 2026), the share price is 13.5% below its 52-week high of ₹1,414.90 and 11.2% above its 52-week low of ₹1,101.00. The share price is down 0.9% over one year and up 6.8% over three months.
| Current Price | ₹1,224.50 |
|---|---|
| Market Cap | ₹1,02,010 Cr |
| BSE Code | 500124 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 23.8 |
| Return on Equity | 11.52% |
| Return on Assets | 5.74% |
| 52-Week Range | ₹1,101.00 – ₹1,414.90 |
| 1-Year Price Change | -0.9% |
| 3-Month Price Change | +6.8% |
| Beta (1Y) | -0.09 |
| Dividend Yield | 0.65% |
| Headquarters | Hyderabad, Telangana |
| Website | www.drreddys.com |
| Revenue | ₹8,698 Cr |
|---|---|
| Net Profit | ₹921 Cr |
| Net Margin | 10.6% |
| EPS (Basic) | ₹11.10 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; and
1. Global Generics-This segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. It also engages in biologics business. 2. Pharmaceutical Services and Active Ingredients (PSAI)-This segment manufactures and markets active pharmaceutical ingredients and intermediates, which are the principal ingredients for finished pharmaceutical products. It also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. 3. Others-This segment engages in the biotechnology business. It develops therapies in the fields of oncology and inf
1. Global Generics-89% 2. Others-0.6% 3. Pharmaceutical Services and Active Ingredients (PSAI)-12.5%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,19,404 Cr | 36.6 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,658 Cr | 22.5 | 18.32% | ₹8,017 Cr | +14.7% |
| Cipla Limited | ₹1,08,090 Cr | 27.9 | 11.74% | ₹7,119 Cr | -14.7% |
| Laurus Labs Ltd | ₹1,06,442 Cr | 119.8 | 17.74% | ₹2,026 Cr | +125.7% |
| Dr.Reddys Lab | ₹1,02,010 Cr | 23.8 | 11.52% | ₹8,698 Cr | -0.9% |
| Mankind Pharma | ₹91,379 Cr | 47.8 | 12.45% | ₹4,031 Cr | -9.9% |
| Aurobindo Pharma Ltd. | ₹90,432 Cr | 26 | 9.93% | ₹9,150 Cr | +41.7% |
| Lupin Ltd | ₹88,018 Cr | 16.5 | 26.91% | ₹8,277 Cr | -1.1% |
| Glenmark Pharmaceuticals Limited | ₹61,142 Cr | 44.9 | 14.07% | ₹4,018 Cr | +16.2% |
Listed by market capitalisation. Ratios are shown for context only.
Dr.Reddys Lab is trading at ₹1,224.50, with a market capitalisation of ₹1,02,010 Cr.
Dr.Reddys Lab operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Dr.Reddys Lab has a P/E of 23.8 and a return on equity of 11.52%.
Dr.Reddys Lab is listed on the BSE under the scrip code 500124.
Dr.Reddys Lab's share price is down 0.9% over one year and up 6.8% over three months. Its 52-week range is ₹1,101.00 to ₹1,414.90.
In Q2 FY27, Dr.Reddys Lab reported revenue of ₹8,698 Cr and net profit of ₹921 Cr, with basic EPS of ₹11.1 (consolidated, parsed from the company's exchange filing).
Data as of 26 Oct 2026. Descriptive market data only — not investment advice.